Peritoneal mesothelioma

Abstract

Malignant peritoneal mesothelioma (MPM) is a rare and lethal disease of the peritoneal lining, with high variability in biologic aggressiveness. Morbidity and mortality of the disease are related to progressive locoregional effects within the abdominal cavity, such as distention, pain, early satiety, and decreased oral intake that can ultimately lead to bowel obstruction and cachexia. The standard of care for patients with resectable disease remains cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), with potential survival outcomes greater than 5 years in appropriately selected patients. Patients with inoperable MPM can be offered systemic treatment, although the disease is usually refractory to standard chemotherapic regimens. Patients with MPM should be treated at high volume centers with strong consideration for inclusion in tumor registries and clinical trials. In 2020, research will continue to explore promising genetic and immunologic targets and focus on refinement of surgical methods to optimize CRS-HIPEC approaches.

Clinical-pathological Characteristics and Prognostic Factors for Malignant Peritoneal Mesothelioma in the Elderly

“…At present, cytoreductive surgery (CRS) combined with HIPEC as the rst-line treatment of MPM has been proved to improve the prognosis of MPM patients [36][37][38][39][40]. A systematic review and meta-analysis showed patients receiving CRS and HIPEC had a median survival time of 29.5-100 months, much longer than that of untreated patients [41].…”

“Omental Cake” in a Patient With Asbestosis Leading to the Diagnosis of Malignant Peritoneal Mesothelioma

“…There are stages I, II, and III, with the corresponding five-year survivals of 87%, 53%, and 29%, respectively. This novel staging system allows better prognostic stratification [ 2 , 8 ].…”

Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin‐targeted therapies

“…The 3 main histologic subtypes of malignant mesothelioma are epithelioid, biphasic, and sarcomatoid, with a median survival of 19, 12, and 4 months, respectively, for pleural mesothelioma 5 . The overall 5‐year survival is significantly better for patients with peritoneal mesothelioma, and these patients tend to have predominantly epithelioid histology 6 …”